Epirus Biopharmaceuticals, a biosimilar startup, has filed for Chapter 7 bankruptcy.  The Boston-based startup had lost approximately 82% of its value by June of 2016, after an announcement that it would cease working on a biosimilar of Remicade (infliximab) to focus on Soliris (eculizumab) and Actemra (tocilizumab), a cut in 40% of its workforce, and replacement of its CEO by a venture capitalist.